Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breaux/Frist Medicare Plan Needs To Encourage Use Of Private Plans - Lilly

Executive Summary

Stronger incentives should be included in the Breaux/Frist Medicare reform plan to move seniors out of the traditional fee-for-service system and into private plans, Lilly Senior VP-Corporate Strategy & Policy Mitchell Daniels told a Senate Special Committee on Aging hearing Feb. 8.

You may also be interested in...



HCFA Claim To Medicare Oversight Helped By Congressional Testimony, DoJ

A proposed Medicare board "may not be the best choice of organizational structure" to oversee a new Medicare premium-support program, Medicare Payment Advisory Commission Chairman Gail Wilensky told a Senate Finance Committee hearing May 4.

HCFA Claim To Medicare Oversight Helped By Congressional Testimony, DoJ

A proposed Medicare board "may not be the best choice of organizational structure" to oversee a new Medicare premium-support program, Medicare Payment Advisory Commission Chairman Gail Wilensky told a Senate Finance Committee hearing May 4.

Clinton Medicare Plan Could Segue Into Breaux-Style Reform - Reischauer

Enactment of President Clinton's add-on Medicare drug benefit could allow for a phase-in of a Breaux/Frist-type premium support model over five to 10 years, Urban Institute President Robert Reischauer, PhD, suggested Feb. 24 at a Senate Finance Committee hearing on the two proposals.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel